Exjade and Blood iron abnormal - a phase IV clinical study of FDA data

Among these 48 people:

How long have people been on Exjade when they have Blood iron abnormal? *

• < 1 month: 14.29 %
• 1 - 6 months: 42.86 %
• 6 - 12 months: 28.57 %
• 1 - 2 years: 14.29 %
• 2 - 5 years: 0.0 %
• 5 - 10 years: 0.0 %
• 10+ years: 0.0 %

What is the gender of people who have Blood iron abnormal when taking Exjade? *

• female: 55.56 %
• male: 44.44 %

What is the age of people who have Blood iron abnormal when taking Exjade? *

• 0-1: 0.0 %
• 2-9: 3.85 %
• 10-19: 0.0 %
• 20-29: 3.85 %
• 30-39: 0.0 %
• 40-49: 26.92 %
• 50-59: 11.54 %
• 60+: 53.85 %

What are other drugs people take besides Exjade? *

1. Jakafi: 6 people, 12.50%
2. Calcium: 5 people, 10.42%
3. Hydrea: 4 people, 8.33%
4. Zantac: 4 people, 8.33%
5. Xarelto: 3 people, 6.25%
6. Sulfamethoxazole: 3 people, 6.25%
7. Bentyl: 3 people, 6.25%
8. Eliquis: 3 people, 6.25%
9. Furosemide: 2 people, 4.17%
10. Digoxin: 2 people, 4.17%

What are other side effects people have besides Blood iron abnormal? *

1. Diarrhea: 16 people, 33.33%
2. Haemoglobin Decreased: 16 people, 33.33%
3. Weakness: 10 people, 20.83%
4. Weight Decreased: 10 people, 20.83%
5. Drug Ineffective: 9 people, 18.75%
6. Serum Ferritin Increased: 7 people, 14.58%
7. Nausea (feeling of having an urge to vomit): 7 people, 14.58%
8. Malaise (a feeling of general discomfort or uneasiness): 7 people, 14.58%
9. Fatigue (feeling of tiredness): 7 people, 14.58%
10. Feeling Abnormal: 6 people, 12.50%

What are the existing conditions these people have? *

1. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 10 people, 20.83%
2. Primary Myelofibrosis (primary disorder of the bone marrow): 6 people, 12.50%
3. Haemochromatosis (body to absorb more iron than usual from food): 5 people, 10.42%
4. Breast Cancer: 5 people, 10.42%
5. Aplastic Anemia: 2 people, 4.17%
6. Thrombosis (formation of a blood clot inside a blood vessel): 1 person, 2.08%
7. Pathological Fracture (broken bone caused by disease): 1 person, 2.08%
8. Osteoporosis (bones weak and more likely to break): 1 person, 2.08%
9. High Blood Cholesterol: 1 person, 2.08%
10. Coronary Heart Disease (narrowing or blockage of the coronary arteries): 1 person, 2.08%

Do you take Exjade and have Blood iron abnormal?

- Check whether Blood iron abnormal is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

---

---

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Exjade:

Blood iron abnormal treatments and more:

How severe was Blood iron abnormal and when was it recovered:

• Blood iron abnormal in Exjade

Expand to all the drugs that have ingredients of deferasirox:

• Blood iron abnormal and drugs with ingredients of deferasirox

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Exjade:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

• Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
• Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
• Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
• Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
• Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .
• Díaz-García JD, Gallegos-Villalobos A, Gonzalez-Espinoza L, Sanchez-Ni?o MD, Villarrubia J, Ortiz A, "Deferasirox nephrotoxicity [mdash] the knowns and unknowns", Nature reviews nephrology, 2014 Oct .
• Riva A, "Comment on: A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Expert opinion on drug safety, 2013 Sep .
• Riva A, "Deferasirox's toxicity", The Lancet, 2013 Jul .
• Kontoghiorghes GJ, "Turning a blind eye to deferasirox's toxicity?", The Lancet, 2013 Apr .
• Kontoghiorghes GJ, "A record number of fatalities in many categories of patients treated with deferasirox: loopholes in regulatory and marketing procedures undermine patient safety and misguide public funds?", Taylor & Francis, 2013 Jan .

---

How the study uses the data?

The study uses data from the FDA. It is based on deferasirox (the active ingredients of Exjade) and Exjade (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

---

---

Recent studies on eHealthMe:

• Drug interactions of Adapalene and Fluoxetine - 2 seconds ago
• Drug interactions of Oxazepam and Timolol - 6 seconds ago
• Drug interactions of Azulfidine and Xarelto - 15 seconds ago
• Could Colchicine cause Blood Pressure Systolic Decreased? - 16 seconds ago
• Could Poteligeo cause Disease Progression? - 25 seconds ago
• Could Feldene cause Gastric Erosions? - 27 seconds ago
• Drug interactions of Trileptal and Bumex - 29 seconds ago
• Drug interactions of Reclast and Rebif - 46 seconds ago
• Drug interactions of Allopurinol and Valsartan And Hydrochlorothiazide - 54 seconds ago
• Drug interactions of Atenolol and Zinecard - 59 seconds ago